Predictors included: time since initial diagnosis of prostate cancer, chemotherapy status, baseline hemoglobin concentration and PSMA PET/CT parameters (molecular imaging TNM (T is primary tumor, N is lymph node, M is distant metastasis) classification and tumor burden). The gene discussed is FOLH1; the disease is neoplasm.